Eli Lilly and Company
1,273.46USD
-33.2300 (-2.54%)
Computing valuation metrics…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on LLY.
Valuation
P/E (TTM)
42.50x
P/E (Forward)
26.97x
EV/EBITDA
28.32x
EV/Revenue
14.83x
P/S (TTM)
14.25x
P/B
33.50x
FCF Yield
0.52%
Dividend Yield
0.54%
Gross Margin
83.40%
Operating Margin
54.22%
Net Margin
33.53%
Peer Comparison — Drug Manufacturers - General
| Company | Mkt Cap | P/E | EV/EBITDA | FCF Yield | Rev Growth | Div Yield |
|---|---|---|---|---|---|---|
| LLYEli Lilly and Company | $1.14T | 42.50x | 28.32x | 0.52% | 47.67% | 0.54% |
| JNJJohnson & Johnson | $635.07B | 40.03x | 19.20x | 2.91% | 5.90% | 2.03% |
Subject metrics from SEC filings where available; peer metrics from cached market data.
| $504.76B |
| 80.69x |
| 18.50x |
| 3.34% |
| 10.20% |
| 2.42% |
| MRKMerck & Co., Inc. | $358.41B | 115.29x | 14.04x | 4.23% | 5.10% | 2.34% |
| NVSNovartis AG | $287.24B | 22.83x | 14.24x | 4.14% | 0.80% | 3.14% |
| AMGNAmgen Inc. | $237.48B | 27.28x | 16.26x | 3.64% | 9.50% | 2.29% |
| GILDGilead Sciences, Inc. | $193.48B | — | 14.71x | 5.05% | 10.20% | 2.10% |
| PFEPfizer Inc. | $171.16B | 39.00x | 8.79x | 7.29% | 2.60% | 5.73% |
| BMYBristol-Myers Squibb Company | $125.59B | 13.54x | 8.43x | 6.46% | 5.70% | 4.10% |